Investigational drug · Phase 3
PCV13i
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Pneumococcal Infections, Streptococcal Infections, Bacterial Infections.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "PCV13i"
First trial start
2025
Nov 14, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PCV13i", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pneumococcal Infections
- Streptococcal Infections
- Bacterial Infections
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "PCV13i" as an intervention, largest first.
- Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)Pivotal-lookingCompleted
CanSino Biologics Inc.Industry
NCT04841369 · 3,420 participants · Start Apr 13, 2021 · Primary completion Mar 30, 2022
Drug: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(CRM197,TT); 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine · For: Pneumococcal Infections; Streptococcal Infections; Bacterial Infections
Sites: Anyang, China
- A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)Pivotal-lookingActive, not recruiting
CanSino Biologics Inc.Industry
NCT07017777 · 600 participants · Start Nov 14, 2025 · Primary completion Feb 15, 2027
Drug: PCV13i; Prevnar 13 · For: Pneumococcal Infections; Streptococcal Infections; Bacterial Infections
Sites: Bangkok, Thailand · 3 sites in all
- Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and AbovePivotal-lookingCompleted
CanSino Biologics Inc.Industry
NCT04100772 · 237 participants · Start May 18, 2020 · Primary completion Jun 23, 2021
Drug: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(CRM197,TT); 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine · For: Pneumococcal Infections; Streptococcal Infections; Bacterial Infections
Sites: Anyang, China
Newest research
PubMed records naming it or its code names, newest first.
- The Safety and Immunogenicity of a 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) in 12-23-Month Children: A Double-Blind, Randomized, Phase III Trial in China.
Xie Z, Wang F, Huang L, et al. · Vaccines (Basel) 2025
- The Safety and Immunogenicity of a 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) in Infants: A Double-Blind, Randomized, Phase III Trial.
Xie Z, Li J, Wang X, et al. · Vaccines (Basel) 2024
Also in development for Pneumococcal Infections
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.